Imugene (ASX:IMU) opened its first Australian site for a phase 1b trial investigating the use of cell therapy azercabtagene zapreleucel as a potential treatment for patients with relapsed or diffused large-B lymphoma, according to a Friday filing with the Australian bourse.
The US portion of the trial showed three patients having a complete response using the therapy, the filing said.
Patient recruitment at the Australian site is slated for November, the filing added.
The company's shares closed up more than 2% Friday.
Price (AUD): $0.05, Change: $+0.001, Percent Change: +2.22%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。